To evaluate the safety and tolerability of MM-093, as compared to placebo, when administered as a monotherapy once a week for 24 weeks after discontinuing IMT therapy. [clinicaltrials_resource:16b2f4cc1c1dfabdab644ca9da2694f2]
60 mg, administered subcutaneously, weekly
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To evaluate the safety and tolerability of MM-093, as compared to placebo, when administered as a monotherapy once a week for 24 weeks after discontinuing IMT therapy. [clinicaltrials_resource:16b2f4cc1c1dfabdab644ca9da2694f2]
60 mg, administered subcutaneously, weekly
Bio2RDF identifier
16b2f4cc1c1dfabdab644ca9da2694f2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:16b2f4cc1c1dfabdab644ca9da2694f2
measure [clinicaltrials_vocabulary:measure]
To evaluate the safety and tol ...... ter discontinuing IMT therapy.
description
60 mg, administered subcutaneously, weekly
identifier
clinicaltrials_resource:16b2f4cc1c1dfabdab644ca9da2694f2
title
To evaluate the safety and tol ...... ter discontinuing IMT therapy.
@en
type
label
To evaluate the safety and tol ...... 2f4cc1c1dfabdab644ca9da2694f2]
@en